Cardiac Myosin Inhibitors as a Novel Treatment Option for Nonobstructive Hypertrophic Cardiomyopathy

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Grant Support/Research Contract - Pfizer; Ionis; Cytokinetics
• Consultant Fee/Honoraria/Speaker's Bureau - Cytokinetics, BMS, Eidos/BridgeBio, Pfizer, Ionis, Lexicon, Attralus, Alnylam, Haya, Alexion, Akros, Prothena, BioMarin, AstraZeneca, and Tenaya